RNS Number: 0096N CVS Group plc 20 November 2024

20 November 2024

CVS Group plc

("CVS" or the "Company")

Result of AGM

CVS, one of the UK's leading providers of integrated veterinary services, announces that at the Company's Annual General Meeting ("AGM") held earlier today, all of the resolutions proposed, as set out in the Notice of AGM, were passed on a poll. Resolutions 1 to 13 were passed as ordinary resolutions and resolutions 14 to 17 were passed as special resolutions.

A summary of proxy votes received for each resolution will shortly be available alongside the Notice of AGM on the Company's website, https://www.cvsukltd.co.uk/investor-centre/agm

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Scott Morrison, Group Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)

 Geoffrey Pelham-Lane
 +44 (0)7733 124 226

 Ginny Pulbrook
 +44 (0)7961 315 138

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK, and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.460 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices) and an online retail business ("Animed Direct").

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.dec. www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END